Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • Harren Jhoti
      • Chris Murray
      • Neil Thompson
      • David Rees
      • Jeremy Carmichael
      • Lee Dawson
      • Neil Jones
      • John Lyons
      • Glyn Williams
      • Mohammad Azab
      • Martin Buckland
      • Harold N. Keer
      • Nipun Davar
      • Yong Hao
      • Joseph Iovino
      • Samuel Jason
      • Shu Lee
      • Shinichi Sato
      • Sameena Sharif
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Guadecitabine (SGI-110) DNMT inhibitor (Treatment Naïve AML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Relapsed/Refractory AML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Relapsed/Refractory MDS or CMML)
      • Guadecitabine (SGI-110) DNMT inhibitor (Solid Tumors)
      • Onalespib (AT13387) HSP90 inhibitor (Solid Tumors)
      • AT7519 CDK inhibitor (Solid Tumors)
      • ASTX727 Oral DNMT inhibitor (Hematologic Malignancies)
      • ASTX660 Dual IAP Antagonist (Solid Tumors & Lymphomas)
      • Kisqali®(ribociclib) CDK4/6 inhibitor (Oncology)
      • AZD3293 (lanabecestat) Beta Secretase (BACE) inhibitor (Alzheimer’s disease)
      • AZD5363 PKB/Akt Inhibitor (Oncology)
      • JNJ42756493 (erdafitinib) FGFr inhibitor (Oncology)
      • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation
  • Partnering
  • Our People
    • Career Opportunities
  • Media
    • Press Releases
      • Press Releases – Archive
    • Conferences & Meetings
    • Presentations & Publications
    • Astex in the News
  • Contact
  • Search
You are here: Home / 2011 / SuperGen Reports 2011 Second Quarter Financial Results

SuperGen Reports 2011 Second Quarter Financial Results

3 August 2011/in 2011, News /by webadmin

SuperGen Reports 2011 Second Quarter Financial Results

/wp-content/uploads/2016/11/logo.png 0 0 webadmin /wp-content/uploads/2016/11/logo.png webadmin2011-08-03 14:32:582016-11-24 14:53:59SuperGen Reports 2011 Second Quarter Financial Results

Copyright © Astex Pharmaceuticals
All rights reserved

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

FDA Accepts DACOGEN® (Decitabine) sNDA Submission in Acute Myeloid Leukemi... SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock...
By continuing to use this website you will be agreeing to our Terms & Conditions, our Privacy Policy, and the use of cookies.continue
Scroll to top